Scilex Holding Co. (SCLX)

$9.25 +2.25 (32.14%)
Market Cap 48.66M
Revenue (ttm) 56.59M
Net Income (ttm) -72.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -128.66%
Debt to Equity Ratio -0.19
Volume 406,000
Avg Vol 125,796
Day's Range N/A - N/A
Shares Out 6.95M
Stochastic %K 97%
Beta 1.19
Analysts Strong Buy
Price Target $367.13

Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 516 4310
Address:
960 San Antonio Road, Palo Alto, United States
JustAGoodOleBoy22
JustAGoodOleBoy22 Jul. 18 at 2:46 AM
$SCLX Don't squeeze the Charmin but Do squeeze the Sharmo .... where is that little Peter pan?
0 · Reply
DjLaFlecha
DjLaFlecha Jul. 18 at 2:27 AM
$SCLX lube them all
0 · Reply
Sacsofcash
Sacsofcash Jul. 18 at 1:55 AM
$SCLX Average Price Target: 4 Wall Street analysts covering Scilex have a consensus rating of "Strong Buy" and an average twelve-month price target of $455.00, with a high forecast of $630.00 and a low forecast of $245.00.
0 · Reply
Awaywithshorts
Awaywithshorts Jul. 18 at 1:45 AM
$SCLX go away troll
0 · Reply
Reallybigbags
Reallybigbags Jul. 18 at 1:25 AM
$SCLX .26 cents not bad
0 · Reply
StockScanners
StockScanners Jul. 18 at 1:25 AM
$SCLX Keep watch if this holds above 8.70
0 · Reply
imshredin2
imshredin2 Jul. 18 at 1:16 AM
$SCLX LOL wouldn't you know I picked this morning to sell the 3 shares I still had after 3? rs's...I managed to turn like $3000 into like $21...I was keeping them to remind me to never drink the Koolaide again it was like having a dried up piece of dog shit on my living room floor for 4 years. GTFOH!
0 · Reply
PatientiaSitVirtus
PatientiaSitVirtus Jul. 18 at 12:56 AM
$SCLX Let’s have some fun, shall we? I’m in the mood for a good laugh. Let’s look at Umbrella girl’s “expert”predictions from yesterday: 1. Said no breakout - Wrong 2. Resistance levels - Wrong 3. Technical analysis - Wrong 4. Chart reading - Wrong 5. Claims to have bought weeks ago, but roots against her own holding with a bearish post - more lies from someone who at the end of the day is simply psychotic. Wow! Umbrella girl was wrong about every single prediction in her long-winded post. I wouldn’t trust her to predict what color the sky will be tomorrow. With Scilex up 36% and counting, it must be extremely painful being her. But hey, she always has her brown-nosed lackey Rank Frank_Poop in her corner! He’s got his nose stuck so far up her butt he can smell her breath. That smelly sycophant clicks the like button on every one of her posts. In the end, Rank Frank is just another submissive weakling with a humiliation kink. Screenshots are easy. Real easy. Hahaha!😁
0 · Reply
IMAUAP
IMAUAP Jul. 18 at 12:17 AM
$SCLX Just another 166 days just like this.
0 · Reply
SexyStockSlayer
SexyStockSlayer Jul. 18 at 12:15 AM
$SCLX posted in May regains compliance and has upcoming trial results presentation • 5M float • cash flow positive • big increase in EPS • recent analysis PT $22
0 · Reply
Latest News on SCLX
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

Jun 23, 2025, 4:50 PM EDT - 24 days ago

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

Jun 5, 2025, 12:05 PM EDT - 6 weeks ago

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025, 9:00 AM EDT - 2 months ago

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025, 9:00 AM EDT - 2 months ago

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Apr 30, 2025, 1:46 PM EDT - 2 months ago

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Apr 22, 2025, 9:00 AM EDT - 3 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Apr 16, 2025, 2:12 PM EDT - 3 months ago

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

Apr 15, 2025, 9:00 AM EDT - 3 months ago

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Apr 11, 2025, 9:00 AM EDT - 3 months ago

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Mar 26, 2025, 8:24 PM EDT - 4 months ago

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Mar 10, 2025, 9:00 AM EDT - 4 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Jan 31, 2025, 9:00 AM EST - 5 months ago

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Jan 21, 2025, 11:49 AM EST - 6 months ago

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Jan 21, 2025, 9:46 AM EST - 6 months ago

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Jan 21, 2025, 9:00 AM EST - 6 months ago

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Jan 21, 2025, 6:00 AM EST - 6 months ago

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Jan 16, 2025, 3:38 PM EST - 6 months ago

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

Dec 30, 2024, 9:00 AM EST - 7 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

Dec 13, 2024, 12:23 PM EST - 7 months ago

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

Scilex Holding Company Announces $17 Million Registered Direct Offering

Dec 12, 2024, 8:21 AM EST - 7 months ago

Scilex Holding Company Announces $17 Million Registered Direct Offering

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Dec 11, 2024, 12:49 PM EST - 7 months ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

Dec 11, 2024, 7:30 AM EST - 7 months ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

Scilex Holding Company Announces Receipt of Notice from Nasdaq

Nov 22, 2024, 6:00 AM EST - 8 months ago

Scilex Holding Company Announces Receipt of Notice from Nasdaq

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Nov 6, 2024, 12:24 PM EST - 9 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

Oct 30, 2024, 6:00 AM EDT - 9 months ago

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Oct 29, 2024, 6:00 AM EDT - 9 months ago

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Oct 28, 2024, 6:00 AM EDT - 9 months ago

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Oct 16, 2024, 4:00 AM EDT - 9 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

Oct 8, 2024, 1:58 PM EDT - 10 months ago

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

Oct 8, 2024, 11:50 AM EDT - 10 months ago

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

Oct 7, 2024, 10:00 AM EDT - 10 months ago

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

ORMP

Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile

Oct 7, 2024, 9:52 AM EDT - 10 months ago

Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile

Top 3 Health Care Stocks That Could Blast Off In September

Sep 10, 2024, 7:27 AM EDT - 11 months ago

Top 3 Health Care Stocks That Could Blast Off In September

AMN PDCO

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Sep 3, 2024, 9:00 AM EDT - 11 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

Aug 30, 2024, 9:00 AM EDT - 11 months ago

Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label

Aug 29, 2024, 9:00 AM EDT - 11 months ago

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label

Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain

Aug 21, 2024, 9:00 AM EDT - 11 months ago

Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain

Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

Aug 9, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Jul 24, 2024, 10:52 AM EDT - 1 year ago

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut

Jul 3, 2024, 10:51 AM EDT - 1 year ago

Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut

Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital

Jul 2, 2024, 6:24 PM EDT - 1 year ago

Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Jul 2, 2024, 5:15 PM EDT - 1 year ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

Jul 2, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.

Jun 20, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.

Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)

Jun 14, 2024, 1:41 PM EDT - 1 year ago

Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)

Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies

Jun 11, 2024, 7:20 PM EDT - 1 year ago

Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies

Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®

Jun 11, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®

Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.

Jun 10, 2024, 11:49 AM EDT - 1 year ago

Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.

Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024

Jun 6, 2024, 2:56 PM EDT - 1 year ago

Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024

Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company

May 30, 2024, 1:19 PM EDT - 1 year ago

Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company

JustAGoodOleBoy22
JustAGoodOleBoy22 Jul. 18 at 2:46 AM
$SCLX Don't squeeze the Charmin but Do squeeze the Sharmo .... where is that little Peter pan?
0 · Reply
DjLaFlecha
DjLaFlecha Jul. 18 at 2:27 AM
$SCLX lube them all
0 · Reply
Sacsofcash
Sacsofcash Jul. 18 at 1:55 AM
$SCLX Average Price Target: 4 Wall Street analysts covering Scilex have a consensus rating of "Strong Buy" and an average twelve-month price target of $455.00, with a high forecast of $630.00 and a low forecast of $245.00.
0 · Reply
Awaywithshorts
Awaywithshorts Jul. 18 at 1:45 AM
$SCLX go away troll
0 · Reply
Reallybigbags
Reallybigbags Jul. 18 at 1:25 AM
$SCLX .26 cents not bad
0 · Reply
StockScanners
StockScanners Jul. 18 at 1:25 AM
$SCLX Keep watch if this holds above 8.70
0 · Reply
imshredin2
imshredin2 Jul. 18 at 1:16 AM
$SCLX LOL wouldn't you know I picked this morning to sell the 3 shares I still had after 3? rs's...I managed to turn like $3000 into like $21...I was keeping them to remind me to never drink the Koolaide again it was like having a dried up piece of dog shit on my living room floor for 4 years. GTFOH!
0 · Reply
PatientiaSitVirtus
PatientiaSitVirtus Jul. 18 at 12:56 AM
$SCLX Let’s have some fun, shall we? I’m in the mood for a good laugh. Let’s look at Umbrella girl’s “expert”predictions from yesterday: 1. Said no breakout - Wrong 2. Resistance levels - Wrong 3. Technical analysis - Wrong 4. Chart reading - Wrong 5. Claims to have bought weeks ago, but roots against her own holding with a bearish post - more lies from someone who at the end of the day is simply psychotic. Wow! Umbrella girl was wrong about every single prediction in her long-winded post. I wouldn’t trust her to predict what color the sky will be tomorrow. With Scilex up 36% and counting, it must be extremely painful being her. But hey, she always has her brown-nosed lackey Rank Frank_Poop in her corner! He’s got his nose stuck so far up her butt he can smell her breath. That smelly sycophant clicks the like button on every one of her posts. In the end, Rank Frank is just another submissive weakling with a humiliation kink. Screenshots are easy. Real easy. Hahaha!😁
0 · Reply
IMAUAP
IMAUAP Jul. 18 at 12:17 AM
$SCLX Just another 166 days just like this.
0 · Reply
SexyStockSlayer
SexyStockSlayer Jul. 18 at 12:15 AM
$SCLX posted in May regains compliance and has upcoming trial results presentation • 5M float • cash flow positive • big increase in EPS • recent analysis PT $22
0 · Reply
Skunky
Skunky Jul. 18 at 12:02 AM
$SCLX 🚂 Breakout train still rolling $9.49 AH. 📈🔥
0 · Reply
Dew8
Dew8 Jul. 17 at 11:10 PM
$SCLX I bought this at 9 pre rs smh
1 · Reply
UnhappyBrit
UnhappyBrit Jul. 17 at 11:04 PM
$SCLX Why is the breaking out? Is there news?
0 · Reply
ToxicAvenger
ToxicAvenger Jul. 17 at 10:41 PM
$SCLX warrants hit .45 ah.. someone or somebody is hedging... shorty getting nervous.
0 · Reply
HostmanG
HostmanG Jul. 17 at 9:06 PM
$SCLX Just $357 to go to breakeven... lol.. but at least we're moving and in the right direction :-)
0 · Reply
ToxicAvenger
ToxicAvenger Jul. 17 at 9:02 PM
$SCLX just the beginning...
1 · Reply
Awaywithshorts
Awaywithshorts Jul. 17 at 8:29 PM
$SCLX Tomorrow
0 · Reply
elitechrisvp
elitechrisvp Jul. 17 at 8:23 PM
$SCLX just be cool Ringo...
0 · Reply
Umbra_Bellator
Umbra_Bellator Jul. 17 at 8:11 PM
$SCLX For me, now the breakout is confirmed, if, I say if, per my previous post, these levels hold through tomorrow's close. All funning aside, one would have to say for any stock, this was a very nice day. Many shareholders needed this to keep hope alive but sadly, many still down thousands, tens of thousands (Im in that camp with SRNE), and some have stated, no proof mine you, down hundreds of thousands. In any event, battle won today, the fight continues. Still at $0.26685714/share factoring in the split. Just saying.
1 · Reply
DENNISF1
DENNISF1 Jul. 17 at 7:58 PM
$SCLX
0 · Reply
DENNISF1
DENNISF1 Jul. 17 at 7:57 PM
$SCLX 🚀 🚀 🚀 🚀 🚀 🚀 🚀? Or not?
1 · Reply
Bat_shtt_crazy
Bat_shtt_crazy Jul. 17 at 7:57 PM
$SCLX I called 7 and 8 away called 9 who’s got the 10? Frank?
0 · Reply